Immune-Related Biomarkers Can Help Guide HER2+ Breast Cancer Tx Immune-Related Biomarkers Can Help Guide HER2+ Breast Cancer Tx
Immune-related gene expression signatures can predict pathologic complete response and could be used to help decide which HER2 therapies to use for which patients, say researchers.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 24, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Tucatinib Plus Trastuzumab Approved for HER2+ CRC Tucatinib Plus Trastuzumab Approved for HER2+ CRC
The combination of HER2-targeted agents is already approved for use in breast cancer and is now is the first treatment approved for HER2-positive colorectal cancer.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 20, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA OKs First Targeted Treatment for HER2-Positive Colorectal Cancer
(MedPage Today) -- The FDA has granted accelerated approval to tucatinib (Tukysa) in combination with trastuzumab (Herceptin) for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer who have progressed... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 19, 2023 Category: Gastroenterology Source Type: news
FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancer
On January 19, 2023, the Food and Drug Administration (FDA) granted accelerated approval to tucatinib (Tukysa, Seagen Inc.) in combination with trastuzumab for RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following fluoropyrimidine-, oxaliplatin-, and (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Seagen Announces FDA Accelerated Approval of Tukysa (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
BOTHELL, Wash.--(BUSINESS WIRE) January 19, 2023 -- Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tukysa (tucatinib) in combination with trastuzumab for adult patients... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 19, 2023 Category: Drugs & Pharmacology Source Type: news
Sacituzumab Govitecan in HR+/HER2- Metastatic Breast Cancer Sacituzumab Govitecan in HR+/HER2- Metastatic Breast Cancer
Is this drug therapy an effective therapeutic option for HR+/HER2- advanced breast cancer? What benefits might this treatment offer over single-agent chemotherapy?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 11, 2023 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
An Impactful Experience With a Patient With Metastatic Breast Cancer An Impactful Experience With a Patient With Metastatic Breast Cancer
Kevin M. Kalinsky, MD, considers the impact of an antibody-drug conjugate in a patient with HER2-low breast cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 6, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact? HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact?
One of the problems with the new subgroup of HER2 low tumors is that using current assays to measure low levels"is like weighing mice on a scale built for elephants," says one expert.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 5, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
A Big Year at the San Antonio Breast Cancer Symposium 2022 A Big Year at the San Antonio Breast Cancer Symposium 2022
Kathy Miller, MD, reflects on the impact of the positive data presented at SABCS for her patients with hormone receptor-positive, HER2-negative breast cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 4, 2023 Category: Consumer Health News Tags: None MDAngle Source Type: news
Advocate for Yourself at the Doctor
Five ways to advocate for yourself and become responsibly selfish when you have HER2-postiive breast cancer (Source: WebMD Health)
Source: WebMD Health - January 4, 2023 Category: Consumer Health News Source Type: news
PIK3CA Mutation Predicts Worse Outcomes in HER2+ Breast Cancer PIK3CA Mutation Predicts Worse Outcomes in HER2+ Breast Cancer
The analysis suggests that PIK3CA mutation is associated with worse pathologic complete response and other outcomes. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 3, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Top Studies in Metastatic Breast Cancer From SABCS 2022 Top Studies in Metastatic Breast Cancer From SABCS 2022
Top studies in metastatic breast cancer from SABCS 2022 focus on practice-changing therapies for HR+/HER2- breast cancer, a follow-up of the monarchE trial, and results of the POSITIVE trial.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 29, 2022 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news
First-Line Regimens With Endocrine Therapy Show Benefits in Breast Cancer
TUESDAY, Dec. 20, 2022 -- First-line regimens with endocrine therapy (ET) may be associated with benefits among patients with human epidermal growth factor receptor 2-positive (ERBB2-positive [formerly HER2-positive]) metastatic breast cancer (MBC),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 20, 2022 Category: Pharmaceuticals Source Type: news
SABCS 2022: New HR+/HER2- Breast Cancer Data Expected SABCS 2022: New HR+/HER2- Breast Cancer Data Expected
Kevin M. Kalinsky, MD, looks forward to SABCS and new data concerning the population of patients with HR+/HER2- breast cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 19, 2022 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
America's top cancer doctor diagnosed with early-stage breast cancer
Dr Monica Bertagnolli, the first female director of the National Cancer Institute at the NIH, revealed today that she has been diagnosed with hormone receptor-positive, HER2-negative breast cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - December 14, 2022 Category: Consumer Health News Source Type: news
